'Qt prolongation' diaporamas de présentation

1.24k views • 100 slides

METHADONE

METHADONE. MELLAR DAVIS, WAEL LASHEEN, DECLAN WALSH. METHADONE. SYNTHETIC PSEUDOPIPERDINE DEVELOPED OVER 50 YEARS AGO DISTINCTLY DIFFERENT FROM ALKALOID OPIOIDS (MORPHINE) (CODEINE) AND SYNTHETIC THEBAINE DERIVATIVES (OXYCODONE). METHADONE. R (L) AND S (D) ENANTIOMER

1.91k views • 81 slides

Treatment During Pregnancy: Gaps in our Knowledge

Treatment During Pregnancy: Gaps in our Knowledge Donald R Mattison Obstetric and Pediatric Pharmacology Research Branch Center for Research for Mothers and Children NICHD, NIH, HHS mattisod@mail.nih.gov 301 451 3823

1.51k views • 77 slides

PHAR 751 Dietary Effects on Metabolism

PHAR 751 Dietary Effects on Metabolism. Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System sbrown@asante.org. Metabolism: P-gp review. Substrate + Inhibitor = Substrate + Inducer = . CYP Metabolism. Cytochrome P450

1.03k views • 70 slides

Sudden Cardiac Death

1.11k views • 68 slides

Headache

1.09k views • 45 slides

CURRENT PHARMACOLOGY & TOXICOLOGY GUIDLINES FOR PHARMACEUTICAL INDUSTRY

CURRENT PHARMACOLOGY & TOXICOLOGY GUIDLINES FOR PHARMACEUTICAL INDUSTRY By Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D Associate Professor Department of Pharmaceutics KLE University BELGAUM - 10 Objective of the Guidance

1.02k views • 43 slides

CURRENT PHARMACOLOGY & TOXICOLOGY GUIDLINES FOR PHARMACEUTICAL INDUSTRY

CURRENT PHARMACOLOGY & TOXICOLOGY GUIDLINES FOR PHARMACEUTICAL INDUSTRY. By. Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D Associate Professor Department of Pharmaceutics KLE University BELGAUM - 10. Objective of the Guidance.

622 views • 43 slides

Drug-Drug Interactions: Inhibition and Induction

Drug-Drug Interactions: Inhibition and Induction. Michael W. Sinz, Ph.D. Metabolism and Pharmacokinetics Bristol Myers Squibb. Pharmaceutical Research Institute Wallingford, CT michael.sinz@bms.com. Potential Impact on Drug Label. Typical Television Advertisement.

2.31k views • 36 slides

Dangerous ECG Findings: And what to do about them!

Dangerous ECG Findings: And what to do about them!. Scott Morsberger, PA-C, MPAS. Scenario #1. 45 Year Old Female. Hx of vagal sounding syncope. PMHx: HTN, Anxiety, OSAS. Lower abd pain/syncope without usual prodrome. Wakes up SOB. Meds: Lisinopril/HCT, Fluoxetine. ED: K+= 2.8.

512 views • 35 slides

Long QT syndrome

Long QT syndrome. Done by: Dr. Ayman Bukhari Dr. Amin Zagzoog Supervised by: Dr. Mona Kholeif Consultant Cardiologist. Introduction. Long QT syndrome (LQTS) is a disorder characterized by a prolongation of

355 views • 35 slides

Case Presentation 18/02/2009 Flip Cloete

Case Presentation 18/02/2009 Flip Cloete. Case 1: 50 Yr Female History: ? Overdose Found in Bed GCS 10/15 En Route: GCS 7/15 Intubated 7 ETT Nil drugs Husband intoxicated No further history . 1 Survey: Intubated on ventilator BP: 194/116 P: 127

449 views • 29 slides

SUDDEN DEATH & ANTIPSYCHOTIC DRUGS

SUDDEN DEATH & ANTIPSYCHOTIC DRUGS. Homayoun Amini M.D. TUMS. Introduction.

433 views • 26 slides

Long QT Syndrome

712 views • 22 slides

Cardiovascular Drugs That Prolong The QT Interval

Cardiovascular Drugs That Prolong The QT Interval. Douglas C. Throckmorton, M.D. U.S. Food & Drug Administration Division of Cardio-Renal Drug Products. Issues. Approval of anti-arrhythmic drugs that prolong the QT interval Sotalol and Dofetilide

510 views • 21 slides

Lab/X-ray/ECG Rounds

Lab/X-ray/ECG Rounds. James Huffman January 15, 2009. 67y.o. Female. Epigastric aching/burning for ~ 4 hours Radiates to LUQ/Left chest, ?back Associate N/V, diaphoresis Onset while walking to car after bingo (she won $50) History of HTN, ++smoking, EtOH abuse. Case: Continued.

251 views • 17 slides

HESI/ILSI Health and Environmental Sciences Institute

HESI/ILSI Health and Environmental Sciences Institute. Workshop session I: Molecular and Cellular Biology Underlying TdP. Co-Chairs: Craig January and Dan Roden Rapportuers: Kristy Bruse and Ying Ying Zhou

158 views • 15 slides

Vernakalant for Conversion of Atrial Fibrillation: FDA Perspective Cardiovascular and Renal Drugs Advisory Committee Bel

Vernakalant for Conversion of Atrial Fibrillation: FDA Perspective Cardiovascular and Renal Drugs Advisory Committee Beltsville, MD December 11, 2007. Ellis F. Unger, M.D. Deputy Director Division of Cardiovascular and Renal Products Center for Drug Evaluation and Research

542 views • 13 slides

Larson RA et al. Proc ASCO 2010;Abstract 6501.

Comparison of Nilotinib and Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd Beyond One Year. Larson RA et al. Proc ASCO 2010;Abstract 6501. Introduction.

204 views • 7 slides

Fingolimod Therapy for Multiple Sclerosis

Fingolimod Therapy for Multiple Sclerosis. Mary A. Willis, MD Neurological Institute The Mellen Center for Multiple Sclerosis Treatment and Research Cleveland Clinic Cleveland, Ohio. Anne H. Cross, MD Professor and Director John L. Trotter Multiple Sclerosis Center

855 views • 6 slides